What's new

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0079/2024

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0079/2024

May 12, 2025 - 11:19
 0
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0079/2024
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0079/2024
Read More

Tags:

Previous Article

Future Hospitality Summit Saudi Arabia 2025: Day Two Highlights

Next Article

HYROX names INTERSPORT as official title partner

Related Posts

Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Date of authorisation: 07/01/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

May 12, 2025  0

Human medicines European public assessment report (EPAR): Xyrem, sodium oxybate, Date of authorisation: 13/10/2005, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR...

May 12, 2025  0

PSUSA/00001606/202409

PSUSA/00001606/202409

May 13, 2025  0